Venlafaxine Hydrochloride Tablet, Extended Release
Product Images NDC 68001-498

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68001-498). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mg 30 Count (150 mg 90s)

Label for Venlafaxine Extended-Release Tablets 150 mg by BluePoint Laboratories. The label shows a package of 30 tablets. It includes storage instructions, manufacturer information (Ascent Pharmaceuticals, Inc.), and guidance for dispensers to provide the medication guide with each dispensing. The National Drug Code (NDC) 68001-498-04 is displayed.*

FDA Label Image

225mg 30 Count (225 mg 90s)

Label for Venlafaxine Extended-Release Tablets 225 mg by BluePoint Laboratories. The label shows the NDC 68001-499-04 and indicates the package contains 30 tablets. It includes storage instructions, dispensing notes, and manufacturer details: Ascent Pharmaceuticals, Inc., for BluePoint Laboratories.*

FDA Label Image

37.5 mg 90s.jpg.jpg

Venlafaxine Extended-Release Tablets 37.5 mg oral tablets label. The label shows the product name, strength, and quantity of 30 tablets. It includes storage instructions, manufacturer as Ascent Pharmaceuticals, Inc., and the labeler BluePoint Laboratories. The label indicates the product is prescription only with NDC 68001-496-04.*

FDA Label Image

75mg 30 Count (75 mg 90s)

Label for Venlafaxine Extended-Release Tablets 75 mg by BluePoint Laboratories. The label indicates this Rx-only prescription drug contains 30 tablets per container. It includes storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc., Central Islip, NY), and a note for authorized dispensers to provide the medication guide with each dispensing.*

FDA Label Image

Structure (Struct)

Chemical structure of venlafaxine hydrochloride showing its molecular components and arrangement, including a cyclohexane ring, methoxyphenyl group, and dimethylamino group with hydrochloride.*

FDA Label Image

Symptoms Table (Symptoms Medication Guide)

A text panel listing warning signs and symptoms that may require medical attention, including thoughts about suicide or dying, severe mood changes, panic attacks, insomnia, irritability, aggressive behavior, dangerous impulses, mania, unusual behavior changes, and visual problems such as eye pain or swelling.*

FDA Label Image

Table (5)

A table displaying the incidence of insomnia and nervousness in placebo-controlled trials for Major Depressive Disorder and other trials. It compares the percentage of patients experiencing these symptoms on Venlafaxine Hydrochloride Extended-Release Capsules versus placebo, with subject numbers listed for each group.*

FDA Label Image

Table (6)

A data table comparing the incidence of treatment-emergent adverse reactions in short-term placebo-controlled clinical trials for Venlafaxine Hydrochloride Extended-Release Capsules versus placebo in patients with major depressive disorder. The table lists body system preferred terms and percentage reporting reactions for each group, covering symptoms across various systems such as cardiovascular, digestive, nervous, respiratory, skin, special senses, and urogenital systems.*

FDA Label Image

Table (7)

Data table presenting the incidence rates of treatment-emergent adverse reactions reported in short-term placebo-controlled clinical trials for venlafaxine hydrochloride extended-release capsules versus placebo in social anxiety disorder patients. It categorizes adverse reactions by body system and compares percentages of subjects reporting each reaction for venlafaxine and placebo groups.*

FDA Label Image

Table-1 (Table 1)

A data table labeled 'Table 1' showing the difference in number of suicidality cases per 1000 patients treated compared to placebo across age ranges. It lists increases for ages under 18 and 18-24, and decreases for ages 25-64 and 65 or older.*

FDA Label Image

Table-2 (Table 2)

Data table presenting the number and percentage of sustained elevations in supine diastolic blood pressure (SDBP) during premarketing studies of venlafaxine hydrochloride extended-release capsules. It compares incidences in major depressive disorder (75-375 mg/day) with other clinical trials (75-225 mg/day).*

FDA Label Image

Table-3 (Table 3)

A table presenting the incidence percentage of sustained elevations in systolic blood pressure (SDBP) in venlafaxine hydrochloride immediate-release tablet studies. The table categorizes the incidence based on daily venlafaxine dose ranges, showing increasing incidence percentages with higher doses.*

FDA Label Image

Table-4 (Table 4)

A data table presenting final on-therapy mean changes from baseline in supine systolic and diastolic blood pressure (mm Hg) for venlafaxine hydrochloride extended-release capsules compared to placebo. The results are shown by indication (Major Depressive Disorder or Other Clinical Trials), study duration, dose range (≤75 mg/day and >75 mg/day), and include supine systolic blood pressure (SSBP) and supine diastolic blood pressure (SDBP) values.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.